A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples

BackgroundThe Estrogen Receptor alpha (ERα) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ERα, which are a direct consequence of the receptors binding preference at specific sites on the chromatin. The identification of ERα binding signatures on a genome-wide level has greatly enhanced our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with respect to its applicability in limited amounts of tumour tissue.ResultsHere, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing.ConclusionWe illustrate the applicability of this refined technology by mapping the ERα genome-wide chromatin binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology permits for a high-resolution transcription factor mapping even from clinical samples.

[1]  V. Theodorou,et al.  Oestrogen receptor–co‐factor–chromatin specificity in the transcriptional regulation of breast cancer , 2011, The EMBO journal.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  A. Floore,et al.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.

[4]  Tao Liu,et al.  CEAS: cis-regulatory element annotation system , 2009, Bioinform..

[5]  Mazhar Adli,et al.  Genome-wide chromatin maps derived from limited numbers of hematopoietic progenitors , 2010, Nature Methods.

[6]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[7]  Jérôme Eeckhoute,et al.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. , 2010, Genes & development.

[8]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[9]  Rory Stark Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer , 2012, RECOMB.

[10]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[11]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[12]  J. Savulescu,et al.  No consent should be needed for using leftover body material for scientific purposes , 2002, BMJ : British Medical Journal.

[13]  Mazhar Adli,et al.  Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq , 2011, Nature Protocols.

[14]  Li Wang,et al.  Single-tube linear DNA amplification (LinDA) for robust ChIP-seq , 2011, Nature Methods.

[15]  Michael D. Wilson,et al.  ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.

[16]  K. Jirström,et al.  Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. , 2006, Journal of the National Cancer Institute.

[17]  E. Liu,et al.  An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.

[18]  Jun Song,et al.  CEAS: cis-regulatory element annotation system , 2006, Nucleic Acids Res..

[19]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[20]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[21]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[22]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[23]  B. Turner,et al.  Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations , 2006, Nature Genetics.

[24]  M. Dillon,et al.  Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence , 2009, Clinical Cancer Research.

[25]  P. V. van Diest No consent should be needed for using leftover body material for scientific purposes. For. , 2002, BMJ.

[26]  Clifford A. Meyer,et al.  Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.